IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors
Posted Jan 08, 2021
BRANFORD, Conn., Jan. 8, 2021 /BiopharmaDive/ -- IsoPlexis, the leader in single-cell functional proteomics, announced a $135 million Series D financing comprised of $85 million in equity securities and a $50 million credit facility. The round was led by Perceptive Advisors with participation from other new investors, Ally Bridge Group and funds and accounts managed by BlackRock, as well as other existing investors. IsoPlexis will use the proceeds from this financing to expand its global commercial and R&D teams, increase operational capacity to satisfy growing demand, and accelerate its next generation single-cell biology product development roadmap.